DNM2 and centronuclear myopathy: Reduction of DNM2 was shown to rescue myotubular myopathy in mice (Mtm1−/y mice) by genetic cross (Cowling et al., 2014) or systemic delivery of antisense oligonucleotides (ASOs) (Tasfaout et al., 2017; Koch et al., 2020), or by reducing DNM2 using an adeno-associated virus-mediated shRNA approach targeting Dnm2 (Tasfaout et al., 2018).